Boston Scientific Accrued litigation increased by 16.0% to $152.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 20.6%, from $126.00M to $152.00M. Over 4 years (FY 2020 to FY 2024), Accrued litigation shows a downward trend with a -23.1% CAGR.
non_current_liabilities_litigation_reserve_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $417.00M | $357.00M | $264.00M | $279.00M | $359.00M | $174.00M | $231.00M | $207.00M | $209.00M | $246.00M | $206.00M | $129.00M | $118.00M | $126.00M | $177.00M | $137.00M | $131.00M | $152.00M |
| QoQ Change | — | -14.4% | -26.1% | +5.7% | +28.7% | -51.5% | +32.8% | -10.4% | +1.0% | +17.7% | -16.3% | -37.4% | -8.5% | +6.8% | +40.5% | -22.6% | -4.4% | +16.0% |
| YoY Change | — | — | — | — | -13.9% | -51.3% | -12.5% | -25.8% | -41.8% | +41.4% | -10.8% | -37.7% | -43.5% | -48.8% | -14.1% | +6.2% | +11.0% | +20.6% |